Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Wednesday, 27 November 1996 16:32 P.M.
The study led a team of doctors to recommend AZT treatment for any pregnant woman with the AIDS virus, regardless of how much virus material can be detected in the blood.
Doctors do not understand how the AIDS virus is passed to a baby. Conventional wisdom holds that 50 to 70 percent of all AIDS babies acquire the virus around the time of birth but it is unclear whether a child becomes infected in the womb or during delivery.
In the past year or so, doctors have observed that the disease seems to progress faster in people who have higher levels of the virus in their blood.
A group of researchers led by Dr. Rhoda Sperling of the Mount Sinai School of Medicine in New York City decided to see if virus levels in the mother influenced the chances of her infant being infected with the AIDS virus. They found that the higher the levels of the virus in a mother's blood the greater the likelihood the disease would be passed on to the baby.
But there were plenty of exceptions to that rule. In fact, when they looked closely at their data, they found that the ability to reduce the amount of virus in the blood is only partly responsible for the ability of AZT to block the spread of the virus to a newborn.
Sperling's team said there was no evidence that even a tiny amount of virus in the blood is safe. "Our data do not suggest that there is an absolute plasma RNA level below which transmission does not occur," they said.
The group also expanded on work, reported two years ago, showing that AZT is effective at preventing the spread of the AIDS virus from a mother to her newborn child in 363 cases. By following 402 infants for 18 months, they confirmed that AZT, made by Glaxo Wellcome and also known as zidovudine, cuts the infection rate among newborns by nearly two thirds.
They reported that 7.6 percent of the babies whose mothers had received AZT became infected themselves compared with 22.6 percent whose mothers had been treated with a placebo.
961127
RE9611A8
Copyright © 1996 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .